Association between endothelial nitric oxide gene intron 4a4b VNTR polymorphism and plasma homocysteine concentrations in Tunisian male patients with myocardial infarction

Nutrition Research

Volumn 32, Issue 5, 2012, Pages 342-346

  Jemaa, Riadh ^a   Kallel, Amani ^a   Sediri, Yousra ^a   Abdessalem, Salem ^a   Mourali, Mohamed Sami ^a   Feki, Moncef ^a   Mechmeche, Rachid ^a   Kaabachi, Naziha ^a  

^a LA RABTA HOSPITAL   (Tunisia)

Author keywords

BMI; Bp; CAD; Homocysteine; Human; MI; Myocardial infarction; Nitric oxide; NO; NOS3; NOS3 gene intron 4a 4b VNTR; PCR; THcy; Vit B12; VNTR

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEINE;

ADULT; AGE; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DYSLIPIDEMIA; ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE; ETHNIC GROUP; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUNISIAN; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; ALLELES; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; INTRONS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TUNISIA;

EID: 84861704555     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.03.013     Document Type: Article

References (34)

1. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lamas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952.
2. Ghilardi G., Biondi M.L., DeMonti M., Bernini M., Turri O., Massaro F., et al. Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene. Clin Chem 2002, 48:989-993.
3. Lüscher T.F., Noll G. It is all in the genes. . .? Nitric oxide synthase and coronary vasospasm. Circulation 1999, 99:2855-2857.
4. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
5. Janssens S.P., Shimouchi A., Quetermous T., Bloch D.B., Bloch K.D. Cloning and expression of cDNA encoding human endothelium derived relaxing factor/nitric oxide synthase. J Biol Chem 1992, 267:14519-14522.
6. Cooke J.P., Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997, 48:489-509.
7. Tesauro M., Thompson W.C., Rogliani P., Qi L., Chaudhary P.P., Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000, 97:2832-2835.
8. Schmidt H.H., Walter U. NO at work. Cell 1994, 78:919-925.
9. Danishpajooh I.O., Gudi T., Chen Y., Kharitonov V.G., Sharma V.S., Boss G.R. Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway. J Biol Chem 2001, 276:27296-27303.
10. Juckett M.B., Weber M., Balla J., Jacob H.S., Vercellotti G.M. Nitric oxide donors modulate ferritin and protect endothelium from oxidative injury. Free Radic Biol Med 1996, 20:63-73.
11. Suh J.R., Oppenheim E.W., Girgris S., Stover P.J. Purification and properties of folate-catabolizing enzyme. J Biol Chem 2000, 275:35646-35655.
12. Durand P., Prost M., Loreau N., Lussier-Cacan S., Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001, 81:645-672.
13. Clarke R., Daly L., Robinson K., Naughten E., Cahalance S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149-1155.
14. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022. Homocysteine Studies Collaboration.
15. Brown K.S., Kluijtmans L.A.J., Young I.S., Woodside J., Yarnell J., McMaster D., et al. Genetic evidence that nitric oxide modulates homocysteine, the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2003, 23:1014-1020.
16. Heil S.G., Den Heijer M., Ven Der Rijt-Pisa B.J.M., Kluijtmans L.A.J., Blom H.J. The 894G>T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels. J Thromb Haemost 2004, 2:750-753.
17. Chrysohoou C., Panagiotakos D.B., Pitsavos C., Antoniades C., Skoumas J., Brown M., et al. Evidence for association between endothelial nitric oxide synthase gene polymorphism (894G>T) and inflammatory markers: the ATTICA study. Am Heart J 2004, 148:733-738.
18. Wang X.L., Mahaney M.C., Sim A.S., Wang J., Blangero J., Almasy L., et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide concentrations. Arterioscler Thromb Vasc Biol 1997, 17:3147-3153.
19. Tsukada T., Yokoyama K., Arai T., Takemoto F., Hara S., Yamada A., et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite concentrations in humans. Biochem Biophys Res Commun 1998, 245:190-193.
20. Cine N., Hatemi A.C., Erginel-Unaltuna N. Association of a polymorphism of the ecNOS gene with myocardial infarction in a subgroup of Turkish MI patients. Clin Genet 2002, 61:66-70.
21. Wang X.L., Sim A.S., Badenhop R.F., McCredie R.M., Wilcken D.E.L. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996, 2:41-45.
22. Gardemann A., Lohre J., Cayci S., Katz N., Tillmanns H., Haberbosch W. The T allele of the missence Glu298Asp endothelial nitric oxide gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerosis risk profile. Atherosclerosis 2002, 160:167-175.
23. Hwang J.J., Tsai C.T., Yeh H.M., Chiang F.T., Hsu K.L., Tseng C.D., et al. The 27-bp tandem repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene is not associated with coronary artery disease in a hospital-based Taiwaneese population. Cardiology 2002, 97:67-72.
24. Jemaa R., Kallel A., Ben Ali S., Omar S., Chabrak S., Elasmi M. Association of a 27-bp repeat polymorphism in intron 4 of endothelial constitutive nitric oxide synthase gene with myocardial infarction in Tunisian patients. Clin Chem Lab Med 2007, 45:1476-1480.
25. World Health Organisation Physical status: the use and interpretation of anthropometry: report of a WHO expert committee, WHO Technical Report Series, no. 854 1995, 321-344. WHO, Geneva.
26. National Institutes of Health, National Heart Lung, Blood Institute Obesity Education Initiative Expert panel on the identification, evaluation, and treatment of overweight and obesity in adults 1998.
27. Marcadet A., O'Connel P., Cohen D. Standardized Southern blot workshop techniques. Histocompatibility Testing 1987, 587-590. New York, Springer. B. Dupont (Ed.).
28. Kerkeni M., Addad F., Chauffert M., Myara A., Ben Farhat M., Miled A. Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin Chem 2006, 52:53-58.
29. Rodriguez Esparragon F.J., Rodriguez Perez J.C., Macias A., Hernandez Trujillo Y., Gonzalez Leiza M., Caballero Y.A. Presion arterial, homocisteina y variantespolimorficasdel gen de la oxidonitricosintasa (NOS3). Nefrologia 2006, 26:559-563.
30. Fisher P.A., Dominguez G.N., Cuniberti L.A., Martinez V., Werba J.P., Ramirez A.J., et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved?. J Am Soc Nephrol 2003, 14:653-660.
31. Stanger O., Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003, 41:1444-1454.
32. Dayal S., Aming E., Bottiglieri T., Boger R.H., Sigmund C.D., Faraci F.M., et al. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemia mice. Stroke 2004, 35:1957-1962.
33. Stamler J.S., Osborne J.A., Jaraki O., Rabbani L.E., Mullins M., Singel D., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993, 91:308-318.
34. Wang J., Dudley D., Wang X.L. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 2002, 22:e1-e4.